Navigation Links
Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
Date:11/4/2008

SAN DIEGO, Nov. 4 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the Rodman & Renshaw Annual Global Investment Conference on Tuesday, November 11, 2008 at 11:35 a.m. EST (8:35 a.m. PST) at the New York Palace Hotel.

Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will present an overview of Anadys and its three clinical programs: ANA598 and ANA773 in hepatitis C and ANA773 in cancer.

The presentation will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at http://www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through November 25, 2008.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines in the areas of hepatitis C and oncology. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 and ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. Risk factors that may cause actual results to differ are discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2007 and Anadys' Form 10-Q for the quarter ended September 30, 2008. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward- looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
2. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
3. Anadys Pharmaceuticals to Present at BIOCOM Investor Conference 2008
4. Anadys Pharmaceuticals to Report Third Quarter 2008 Financial Results
5. Anadys Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
6. Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
7. Anadys Pharmaceuticals to Report Second Quarter 2008 Financial Results
8. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
10. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
11. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... 2016  Discovery Laboratories, Inc. (NASDAQ: DSCO ... KL4 surfactant therapies for respiratory diseases, today announced ... inducement award as a component of employment compensation ... President and Chief Executive Officer.  The award was ... 1, 2016 and granted as an inducement material ...
(Date:2/3/2016)... Ascendis Pharma A/S (Nasdaq: ASND ), ... TransCon technology to address significant unmet medical needs, today ... Leerink Partners Global Healthcare Conference Location: , Waldorf ... 2016 Time:  , 11:55am EST www.ascendispharma.com ... An audio webcast of this event will be posted ...
(Date:2/3/2016)... , Feb. 3, 2016 New ... more than $1 million for researchers in ... on health-related research that demonstrates exciting potential.   ... of funding for the New Jersey Health Foundation Research ... members at these educational institutions— Princeton University, Rutgers ...
(Date:2/3/2016)... ... 2016 , ... ProMIS Neurosciences is currently in the process ... propagating strains of Amyloid beta involved in Alzheimer’s disease. The Company plans to ... on from the first misfolded Amyloid beta target announced on Nov. 12, 2015, ...
Breaking Biology Technology:
(Date:1/11/2016)... CHICAGO , Jan. 11, 2016  higi, ... via nearly 10,000 retail locations, web and mobile, ... than $40 million from existing investors. ... will be devoted to further innovate higi,s health ... app and web portal – including expanding services ...
(Date:1/7/2016)... -- This BCC Research report studies the global as ... identifying newer markets and exploring the expansion of the ... Includes forecast from 2015 to 2020. Use ... the expansion of the present application market for various ... technology, determine its current market size, and estimate the ...
(Date:1/6/2016)... 2016  Varam Capital, a provider of micro-finance inclusion ... deliver advanced authentication solutions to their clients. Varam supplies ... A loan of a few thousand rupees may make ... ability to purchase livestock or equipment for a small ... for a local store. ...
Breaking Biology News(10 mins):